A Paired Case Controlled Study Comparing the Short-term Outcomes of Da Vinci RATS and VATS Approach for Non-small Cell Lung Cancer

• Main Authors: Feng DAI, Shiguang XU, Wei XU, Renquan DING, Bo LIU, Hao MENG, Yunteng KANG, Xiangrui MENG, Jie LIN, Shumin WANG
• Format: Article
• Language: zho
• Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-03-01
• Series: Chinese Journal of Lung Cancer
• Subjects: Robot-assisted thoracic surgery; Video-assisted thoracic surgery; Lung neoplsms; Short-term outcomes; Matching case-control study
• Online Access: http://dx.doi.org/10.3779/j.issn.1009-3419.2018.03.18
• ISSN: 1009-3419; 1999-6187

Background and objective Da Vinci Surgical System is one of the greatest inventions of the 20th century, which represents the development direction of the precise minimally invasive surgical techniques, the aim of this study was to comparing the short-term outcomes between da Vinci robot-assisted lobectomy and video-assisted thoracic surgery (VATS) lobectomy for non-small cell lung cancer. Methods 45 pairs of non-small cell lung cancer patients underwent pulmonary lobectomy with da Vinci Robotic assisted thoracoscopic (RATS) and VATS approach during the same period from January 2014 to January 2017. The operative time, estimated blood loss (EBL), total number and total groups of dissected lymph nodes, postoperative duration of drainage, the first day volume of drainage, total volume of drainage were compared. Results No perioperative death and convertion to thoracotomy occured in both groups. There were significant difference between RATS group and VATS group in EBL [(50.30±32.33) mL vs (208.60±132.63) mL], the first day volume of drainage [(275.00±145.42) mL vs (347.60±125.80) mL], the dissected total number [(22.67±9.67) vs (15.51±5.41)] and total team [(6.31±1.43) vs (4.91±1.04)] of lymph node. There were no significant difference in other outcomes. Conclusion RATS is safe and effective and took better short-outcomes than VATS in non-small cell lung cancer.